Wainwright: Non-mRNA COVID-19 Option Underappreciated
- HC Wainwright says safety concerns were noted for Novavax Inc's COVID-19 vaccine, but the strength of data showed that benefit outweighs risks.
- With a 21-0 vote (one abstention) for Emergency Use Authorization (EUA), moved the first traditional, protein-based COVID-19 vaccine closer to becoming available in the U.S.
- HC Wainwright believes six cases of heart inflammation observed in clinical studies are notable. The VRBPAC did not conclude that it was a risk that outweighed the benefits.
- As experience with the shot is limited, long-term safety remains to be established, and the analysts acknowledge that a causal relationship between myocarditis/pericarditis and vaccination needs further study.
- Incidences of myocarditis/pericarditis ranging as high as 97.3 per million doses administered have been observed by the CDC for currently authorized COVID-19 vaccines from Pfizer Inc / BioNTech SE and Moderna Inc .
- "We believe the option to have a vaccine available that does not use messenger RNA (mRNA) technology is underappreciated," the analysts write.
- It reaffirms projections of $4.4 billion and $5.8 billion in global sales in 2022 and 2023, respectively, and reiterates a Buy rating and a price target of $207.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.